Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Sanofi/QLT Phototherapeutics

Executive Summary

Sanofi/QLT Phototherapeutics: Photofrin (porfimer sodium) photodynamic therapy supplemental NDA submitted Feb. 10 for reduction of obstruction and palliation of symptoms in patients with obstructing endobronchial non-small cell lung cancer, and for treatment of endobronchial carcinoma in situ or microinvasive NSCLC in patients for whom surgery and radiotherapy are not indicated. Photofrin is approved for palliative treatment of esophageal cancer...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029725

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel